NOVARTIS PHARMACEUTICALS UK LIMITED

1. NOVARTIS PHARMACEUTICALS UK LIMITED 1997-03-03 → present
2. SANDOZ PHARMACEUTICALS (UK) LIMITED 1992-01-01 → 1997-03-03
3. SANDOZ PRODUCTS LIMITED 1911-12-08 → 1992-01-01

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have considered the financial position of the company as at the balance sheet date, including the net assets of £144,450,000 and net current assets of £101,907,000. The company also has a broad customer base, and a strong history of profitable operations. There are no indications that this will not continue to be the case through the foreseeable future. Noting the considerable financial resources available to the company, alongside the company's access to Novartis's global cash pooling arrangement, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future, covering a period of at least 12 months from the issue of the financial statements. Therefore, they have prepared the financial statements on the going concern basis.”

Group structure

1. NOVARTIS PHARMACEUTICALS UK LIMITED · parent
   1. Neutec Pharma Limited 100% · UK · Non-trading

Significant events

• “On 14 December 2024, board of directors of Gyroscope Therapeutics Limited (a Novartis Group company in UK) decided to transfer it's business with the exception of the office lease to Novartis Pharmaceuticals UK Limited. The agreement to transfer Gyroscope's residual activities to Novartis Pharmaceuticals UK Limited was resolved on 14 December 2024 and signed on 17 June 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +17.8%

  £630,898,000 → £743,034,000

• Cash

  —

  Not reported

• Net assets

  +9.8%

  £131,569,000 → £144,450,000

• Employees

  +56.8%

  848 → 1,330

• Operating profit

  +28.4%

  £36,931,000 → £47,419,000

• Profit before tax

  +34.2%

  £34,152,000 → £45,831,000

• Wages

  +10.7%

  £99,936,000 → £110,670,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers